Neurofilament levels are associated with blood–brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis
暂无分享,去创建一个
M. Ramanathan | M. Dwyer | R. Zivadinov | E. Havrdová | N. Bergsland | J. Kuhle | C. Barro | B. Srpova | D. Horáková | T. Uher | J. Krasensky | M. Vaněčková | M. Týblová | J. Oechtering | H. Posová | Mason McComb | Shery Galkin | Christian Barro
[1] L. Kappos,et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response , 2019, Neurology.
[2] K. Blennow,et al. Vitamin D supplementation and neurofilament light chain in multiple sclerosis , 2018, Acta neurologica Scandinavica.
[3] Ludwig Kappos,et al. Neurofilaments as biomarkers in neurological disorders , 2018, Nature Reviews Neurology.
[4] K. Blennow,et al. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis , 2018, Journal of Neuroinflammation.
[5] Ludwig Kappos,et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis , 2018, Brain : a journal of neurology.
[6] David H. Miller,et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.
[7] K. Blennow,et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein , 2017, Neurology.
[8] M. Dwyer,et al. A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long‐Term Comparative Study , 2017, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[9] G. DeLuca,et al. Vascular pathology in multiple sclerosis: reframing pathogenesis around the blood-brain barrier , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.
[10] K. Blennow,et al. Serum concentrations of the axonal injury marker neurofilament light protein are not influenced by blood-brain barrier permeability , 2017, Brain Research.
[11] Ludwig Kappos,et al. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis , 2017, Annals of neurology.
[12] J. Salzer,et al. Vitamin D and axonal injury in multiple sclerosis , 2016, Multiple sclerosis.
[13] M. Ramanathan,et al. Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later , 2016, Multiple sclerosis.
[14] M. Sormani,et al. Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis , 2015, Multiple sclerosis.
[15] M. Ramanathan,et al. Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients[S] , 2015, Journal of Lipid Research.
[16] G. Ortiz,et al. Role of the blood-brain barrier in multiple sclerosis. , 2014, Archives of medical research.
[17] A. Vandamme,et al. CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis , 2014, Journal of Neuroinflammation.
[18] M. Dwyer,et al. Thalamic atrophy is associated with development of clinically definite multiple sclerosis. , 2013, Radiology.
[19] M. Ramanathan,et al. Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study , 2013, PloS one.
[20] Dana Horakova,et al. Volumetric MRI Markers and Predictors of Disease Activity in Early Multiple Sclerosis: A Longitudinal Cohort Study , 2012, PloS one.
[21] S. Amor,et al. Phagocytosis of neuronal debris by microglia is associated with neuronal damage in multiple sclerosis , 2012, Glia.
[22] M. De Paschale,et al. Serological diagnosis of Epstein-Barr virus infection: Problems and solutions. , 2012, World journal of virology.
[23] F. Hanefeld,et al. Paediatric and adult multiple sclerosis: age-related differences and time course of the neuroimmunological response in cerebrospinal fluid , 2009, Multiple sclerosis.
[24] M. Barnett,et al. The macrophage in MS: just a scavenger after all? Pathology and pathogenesis of the acute MS lesion , 2006, Multiple sclerosis.
[25] Gavin Giovannoni,et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. , 2005, Archives of neurology.
[26] A. Minagar,et al. Pathogenesis of brain and spinal cord atrophy in multiple sclerosis. , 2004 .
[27] Alireza Minagar,et al. Blood-brain barrier disruption in multiple sclerosis , 2003, Multiple sclerosis.
[28] B. Trapp,et al. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences , 2001, Current opinion in neurology.
[29] H. Wada. Blood-brain barrier permeability of the demented elderly as studied by cerebrospinal fluid-serum albumin ratio. , 1998, Internal medicine.
[30] A. Reder,et al. Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. , 1997, The Journal of clinical investigation.
[31] J. Benjamins,et al. Multiple sclerosis. Oligodendrocyte proliferation and differentiation in fresh lesions. , 1989, Laboratory investigation; a journal of technical methods and pathology.